This report was recently updated on April 12 2024 with the latest and most recent
market numbers
Global Preclinical Imaging (In-Vivo) Market Size, Trends, and Analysis- Forecasts To 2026 By Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), By Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
For drug discovery and preparation, preclinical imaging (In-Vivo) is used in live animal testing. Preclinical imaging is also used to track patient reactions and look for early signs of efficacy. The advent of in vivo imaging technologies has made it possible to examine disease at the molecular level in a quantitative manner. In vivo imaging serves as a link between in vitro exploratory and in vivo clinical testing, allowing for the direct and rapid transmission of preclinical findings from animal models to human clinical trials. Neurological disorders, autoimmune conditions, cancers, and cardiovascular diseases are the major disease fields addressed by in vivo preclinical imaging.
Preclinical imaging in vivo is expected to develop at a rapid pace in the near future, due to factors such as the technology advances and a rise in the incidence of chronic diseases like rheumatoid arthritis, neurological diseases, cancer, and cardiovascular disease, which are boosting the preclinical imaging market worldwide. The rise in patient population, expanded prospects for low-cost clinical and preclinical trials, and government funding for R&D initiatives are projected to create growth potential for market participants. Technological advancements in molecular imaging, growing demand for non-invasive small animal imaging methods, and an expansion in preclinical research funding from both private and public institutions are among the key factors driving the growth of the preclinical imaging market.
Molecular imaging is a multidisciplinary field that includes molecular engineering, computer science, chemistry, biology, and medicine. It is capable of non-invasive and real-time simulation and measurement of pathological and physiological processes in living organisms at the molecular or cellular level.
Multimodal molecular imaging can improve clinicians' capacity to conduct staging, surveillance, planning and treatment advice, monitoring therapy effectiveness, screening, prognosis, and predicting recurrence in the clinical care of a variety of diseases.
The M2 framework and suite of products produced by Aspect Imaging allow researchers to use the strength and quantitative observations of MRI for small animal phenotyping and drug discovery without the expense, difficulty, or technological strain associated with conventional MRI systems. The market's main growth drivers include a rise in the number of pharmaceutical firms and clinical testing organizations, as well as expanded uses of In-Vivo imaging in pre-clinical research, real-time data collection, and high-resolution modalities.
Insufficient research laboratory facilities, specialized equipment, and a scarcity of qualified research staff in developing markets, as well as the need for high-end devices, are probably the major limitations of the preclinical imaging (In-Vivo) market. Global clinical research programs, as well as technical advances associated with pre-clinical trials, would provide the basis for future expansion.
 Market.png)
On the basis of the modality, the market has been segmented into Ultrasound, PET, Photoacoustic Imaging, SPECT, MRI, Optical Imaging, Magnetic Particle Imaging, and CT. Because of the widespread use of imaging systems in preclinical research studies around the world, the massive cost of systems, and the production and commercialization of technically sophisticated new preclinical imaging technologies, the ultrasound segment is projected to expand at a faster CAGR over the next 5 years (2021-2026). Micro Ultrasound played a major role in 2020 and is expected to rise at the highest rate, owing to its wide variety of applications and effectiveness in conducting research on small animal models. Due to the increased use of these modalities and the advent of the new technology in these segments, other modalities such as Micro-CT and Optical Imaging are also expected to have the highest growth. In preclinical imaging, MRI and PET are often used. For high-quality performance, a mixture of imaging methods, such as PET and CT, is often used.
On the basis of the reagent, the market has been classified into SPECT Probes, Contrast Agents, Optical Imaging Reagents, and PET Tracers. The preclinical optical imaging reagents segment is expected to account for the largest share segment of the market. Technological advances that benefit animal welfare, cost-effective techniques, alternate models, the demand for medical devices, an aging population, rising health consciousness within the population, massive investments in R&D, and the growth associated with the pharmaceutical sector are some of the factors that are boosting demand for the optical preclinical imaging reagents.
 Market.png)
Because of the accelerated acceptance of various types of modalities by end-users, technical advancements, a strong research and development system for life science research, rapid adoption of new molecular imaging technologies, a large presence of pharmaceutical and biotechnology firms, and an increase in the incidence of chronic diseases such as cardiovascular disease, cancer, and others, North America leads the preclinical imaging market. Owing to a rising public understanding of health care and an increase in R&D to develop, Europe is the second-largest region for preclinical imaging. Due to a growth in the number of people, increased opportunities for reduced cost clinical and preclinical trials, and government funding for research and development programs, Asia Pacific is projected to expand at a faster pace. This is owing to ongoing government funding for pharmaceutical and biotechnology R&D, growing public-private investments to support radioisotope manufacturing, an increase in translational research activities, and a changing regulatory situation across major Asian nations. Thus, the clinical research redistributing market is blasting in rising nations, for example, China and India.
FUJIFILM Holdings Corporation, MR Solutions Ltd., Bruker Corporation, Trifoil Imaging, Mediso Ltd, Aspect Imaging, LI-COR Biosciences, MILabs B.V., PerkinElmer, Inc., and Miltenyi Biotec GmbH are some major players competing in the global preclinical imaging market.
Please note: This is not an exhaustive list of companies profiled in the report.
FUJIFILM VisualSonics Inc. announced the launch of the new Vevo LAZR-X in February 2017, which combines high-frequency ultrasound and photoacoustic imaging methods for animal research.
Bruker unveiled the latest Skyscan 1273 benchtop 3D x-ray microscope based on micro-CT technology in February 2019. It is used for non-destructive 3D imaging and encompasses a wide range of industrial and scientific applications.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Pre-Clinical Imaging (In-Vivo) Industry Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Modalities Overview
2.1.3 Reagents Overview
2.1.4 Regional Overview
Chapter 3 Pre-Clinical Imaging (In-Vivo) Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Increasing patient population in developed counties
3.3.1.2 The rising prevalence of cancer and infectious cases
3.3.2 Industry Challenges
3.3.2.1 High cost associated with MRI and CT scan in low income countries
3.4 Prospective Growth Scenario
3.4.1 Modalities Growth Scenario
3.4.2 Reagents Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Pre-Clinical Imaging (In-Vivo) Market, By Modalities
4.1 Modalities Outlook
4.2 Optical Imaging
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 PET
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
4.4 SPECT
4.4.1 Market Size, By Region, 2016-2026 (USD Million)
4.5 CT
4.5.1 Market Size, By Region, 2016-2026 (USD Million)
4.6 MRI
4.6.1 Market Size, By Region, 2016-2026 (USD Million)
4.7 Ultrasound
4.7.1 Market Size, By Region, 2016-2026 (USD Million)
4.8 Photoacoustic Imaging
4.8.1 Market Size, By Region, 2016-2026 (USD Million)
4.9 Magnetic Particle Imaging
4.9.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Pre-Clinical Imaging (In-Vivo) Market, By Reagents
5.1 Reagents Outlook
5.2 Optical Imaging Reagents
5.2.1 Market Size, By Region, 2016-2026 (USD Million)
5.3 Contrast Agents
5.3.1 Market Size, By Region, 2016-2026 (USD Million)
5.4 PET Tracers
5.4.1 Market Size, By Region, 2016-2026 (USD Million)
5.5 SPECT Probes
5.5.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 6 Pre-Clinical Imaging (In-Vivo) Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2016-2026 (USD Million)
6.2.2 Market Size, By Modalities, 2016-2026 (USD Million)
6.2.3 Market Size, By Reagents, 2016-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.2.4.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.2.5.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2016-2026 (USD Million)
6.3.2 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.3 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.4.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.5.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.6.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.7.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.8.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.3.9.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2016-2026 (USD Million)
6.4.2 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.3 Market Size, By Reagents, 2016-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.4.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.5.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.6.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.7.2 Market size, By Reagents, 2016-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.4.8.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2016-2026 (USD Million)
6.5.2 Market Size, By Modalities, 2016-2026 (USD Million)
6.5.3 Market Size, By Reagents, 2016-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.5.4.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.5.5.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.5.6.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2016-2026 (USD Million)
6.6.2 Market Size, By Modalities, 2016-2026 (USD Million)
6.6.3 Market Size, By Reagents, 2016-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.6.4.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.6.5.2 Market Size, By Reagents, 2016-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Modalities, 2016-2026 (USD Million)
6.6.6.2 Market Size, By Reagents, 2016-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 FUJIFILM Holdings Corporation
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 MR Solutions Ltd
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Bruker Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Trifoil Imaging
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Mediso Ltd
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Aspect Imaging
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 LI-COR Biosciences
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 MILabs B.V.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 PerkinElmer, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Other Companies
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
The Global Preclinical Imaging (In-Vivo) Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Preclinical Imaging (In-Vivo) Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
